KR20230040551A - Composition for improving, preventing or treating premenstrual syndrome symptom comprising fermented Pueraria thunbergiana extract as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for improving, preventing, or treating a premenstrual syndrome comprising a kudzu fermented product by inoculating and fermenting a kudzu extract with Lactobacillus paracasei JS1 (accession number: KCCM12288P) strain.

Description

Composition for improving, preventing or treating premenstrual syndrome comprising fermented Pueraria thunbergiana extract as an active ingredient}

The present invention relates to a composition for improving, preventing, or treating premenstrual syndrome, including fermented arrowroot.

The female reproductive cycle is regulated by hormones secreted by the pituitary gland and ovaries. Since hormones are secreted at regular intervals, menstruation under the influence of hormones also has a cycle. The menstrual cycle repeats the follicular phase, ovulation phase, luteal phase, and menstruation. Due to rapid changes in hormones during the luteal phase, more than 90% of women suffer from premenstrual syndrome (PMS). Premenstrual syndrome (PMS) is characterized by physical and psychological symptoms that occur repeatedly before menstruation. Physical symptoms such as muscle pain, breast pain, digestive problems, headaches, and acne, and mental symptoms such as depression, anxiety, sensitivity, and anger appear.

Although the specific cause and mechanism of PMS are not clear, it is known that an imbalance between estrogen and progesterone, decreased serotonin, and increased secretion of prolactin are known to cause PMS. Prolactin is a lacto-stimulating hormone secreted by the anterior pituitary gland. When progesterone secretion is lower than estrogen, prolactin secretion increases. On the other hand, estrogen is a hormone secreted by the ovaries, adrenal cortex, fat cells, etc., and plays a role in developing the endometrium and preventing the secretion of follicle stimulating hormone (FSH) from the pituitary gland. Estrogen is a hormone that has a propensity to promote cell proliferation, and excessive secretion can cause endometritis, breast cancer, and acne by promoting keratinization of hair follicle cells. Progesterone is a hormone that regulates estrogen and is responsible for thickening the lining of the uterus. Therefore, when estrogen increases during the luteal phase and progesterone decreases and prolactin secretion increases, premenstrual syndrome occurs. In addition, estrogen promotes the production of prostaglandin (PG), which further exacerbates dysmenorrhea, inflammation, and vasoconstriction.

No. 10-2045903 No. 10-2145347

An object of the present invention is to provide a composition having excellent effects in improving, preventing or treating premenstrual syndrome, including fermented kudzu extract using a Lactobacillus paracasei JS1 (Accession Number: KCCM12288P) strain.

The present invention provides a food composition for improving premenstrual syndrome, comprising a fermented arrowroot extract obtained by inoculating an arrowroot extract with Lactobacillus paracasei JS1 (Accession Number: KCCM12288P) strain.

In the present invention, the kudzu extract may be preferably extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

In the present invention, the composition preferably further contains iron.

In the present invention, the fermented kudzu product preferably suppresses the secretion of prolactin, estradiol, and PGE2.

In the present invention, the fermented kudzu product preferably increases the secretion of LH and FSH.

In the present invention, it is preferable that the fermented kudzu product increases the secretion of iron and hemoglobin.

In addition, the present invention provides a pharmaceutical composition for preventing or treating premenstrual syndrome comprising a fermented arrowroot extract obtained by inoculating an arrowroot extract with Lactobacillus paracasei JS1 (accession number: KCCM12288P) strain.

The present invention can provide a composition excellent in improving, preventing or treating premenstrual syndrome by treating fermented kudzu extract obtained by inoculating and fermenting Lactobacillus paracasei JS1 (Accession Number: KCCM12288P) strain.

1 is a diagram showing the secretion of prolactin according to whether or not the fermented kudzu product and iron were mixed.
2 is a diagram showing the secretion of estradiol according to whether or not the fermented kudzu product and iron were mixed.
Figure 3 is a diagram showing the secretion of luteinizing hormone (luteinizing hormone) according to whether or not the fermentation product and iron mixture treatment.
Figure 4 is a diagram showing the secretion of follicle stimulating hormone (follicle stimulating hormone) according to whether or not the fermented kudzu and iron mixture treatment.
5 is a diagram showing the amount of secretion of prostaglandin E2 according to whether or not the fermented kudzu product and iron were mixed.
Figure 6 is a diagram showing the amount of iron (iron) secretion according to whether or not the fermented kudzu and iron mixture treatment.
7 is a diagram showing the amount of hemoglobin secretion according to whether arrowroot fermented product and iron were mixed.

The present invention relates to a food composition for improving premenstrual syndrome and a composition for preventing or treating premenstrual syndrome, including fermented arrowroot extract obtained by inoculating a kudzu extract with Lactobacillus paracasei JS1 (Accession Number: KCCM12288P) strain and fermenting it provides

The Lactobacillus paracasei JS1 strain of the present invention was deposited with the Korea Microorganism Conservation Center on July 13, 2018 and was given accession number KCCM12288P.

Kudzu ( Pueraria thunbergiana BENTH.) is used as a plant that contains a large amount of starch in its roots, and is also eaten by making brown powder. In oriental medicine, the dried root is used as a medicinal material called galgeun, and it is known to have the effects of sweating, antipyretic, and antispasmodic.

In the present invention, iron has a common meaning in the technical field to which the invention pertains in the context of iron consumed by humans or animals. Thus, the term includes heme iron, non-heme iron, element iron (also known as reduced iron), complexed iron, and chelated iron. (chelated iron), iron salts, and other forms suitable for human or animal consumption. Iron for ingestion may be obtained from a number of sources known to those skilled in the art. For example, iron for ingestion may be obtained from animal food sources such as red meat, fish or poultry. Such iron is commonly referred to as heme iron. Iron for consumption can also be obtained from plant food sources such as vegetables and fruits. Such iron is commonly referred to as non-heme iron. Ingestible iron may also be obtained from microbial sources, such as green algae.

Dietary iron can also be obtained from inorganic sources. For example, ferrous and ferric salts are sources of ingestible iron, such as ferrous sulfate, ferrous fumarate, ferrous succinate, ferrous gluconate, ferrous lactate. , iron glutamate, and ferrous glycine. Additionally, elemental iron powder can also be used as a source of ingestible iron.

The extract according to the present invention may be obtained by extraction and separation from nature using an extraction and separation method known in the art, and the "extract" defined in the present invention refers to arrowroot ( Pueraria thunbergiana BENTH) using an appropriate solvent. .), and includes, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. As a suitable solvent for extracting the extract from the arrowroot ( Pueraria thunbergiana BENTH.), any food science/pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto, For example, purified water, methanol, ethanol, propanol, isopropanol, alcohol having 1 to 4 carbon atoms including butanol, acetone, ether Various solvents such as benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination. As an extraction method, any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method.

There is no limitation on the preparation method of the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention can be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying of the primary extract extracted by the above-described hot water extraction or solvent extraction method. In addition, a fraction further purified from the primary extract using various chromatography such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography you can also get Therefore, in the present invention, the extract is a concept that includes all extracts, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and dilutions, concentrates, or dried products thereof.

On the other hand, in the present invention, arrowroot extract is preferably extracted using alcohol (ethanol), and preferably extracted with 20 to 40 (v/v)% alcohol. The fermented kudzu product of the present invention is obtained by inoculating and fermenting the kudzu extract with Lactobacillus paracasei JS1 (accession number: KCCM12288P) strain.

In the present invention, it was found that the treatment of fermented arrowroot alone or the mixture of fermented arrowroot and iron in a weight ratio of 40 to 60: 1 showed an excellent improvement effect on premenstrual syndrome. Prefemin, a drug for improving, preventing or treating premenstrual syndrome, only decreases prolactin secretion, decreases estradiol secretion, increases LH (luteinizing hormone) secretion, and PGE2 (prostaglandin E2) secretion The effect of decreasing iron and hemoglobin secretion was marginally limited. On the other hand, the fermented kudzu product or the fermented kudzu product containing iron has the effect of reducing the amount of prolactin secretion in an individual with hyperprolactinemia induced, as well as reducing the secretion of estradiol, increasing the secretion of LH and FSH (follicle stimulating hormone), PGE2 It has been shown to be able to improve premenstrual syndrome more effectively, relieve inflammation that occurs in the uterus before and after menstruation, and improve anemia that may occur before and after menstruation, as it has excellent secretion reduction and iron and hemoglobin secretion increase effects. .

The food composition of the present invention may be, for example, a health functional food composition, and may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional food compositions, in addition to containing an extract as an active ingredient. Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agents described above, natural flavoring agents (thaumatin), stevia extracts (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The food composition of the present invention is formulated in the same way as the following pharmaceutical composition and can be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. there is

The fermented kudzu product or the mixture of the fermented kudzu product and iron content of the present invention is preferably a beverage, and in the case of beverages, it has the advantage of easy oral intake.

In addition, the food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, in addition to extracts that are active ingredients. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain natural fruit juice and fruit flesh for preparing fruit juice beverages and vegetable beverages.

The health functional food composition of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like. In the present invention, 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to the Health Functional Food Act No. 6727, and the structure and function of the human body It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions. The health functional food of the present invention may contain ordinary food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and general test methods approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the relevant standards and standards. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations. For example, a health functional food in the form of a tablet is obtained by granulating a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives in a conventional manner, and then adding a lubricant or the like to compression molding, or The mixture can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a flavoring agent or the like, if necessary. Among capsule-type health functional foods, hard capsules can be prepared by filling a mixture in which the active ingredient of the present invention is mixed with additives such as excipients in a normal hard capsule. It can be prepared by filling a mixture mixed with gelatin in a capsule base. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention mixed with an excipient, binder, disintegrant, etc. by a conventionally known method, and can be coated with sucrose or other coating agent if necessary, Alternatively, the surface may be coated with a material such as starch or talc. Health functional food in the form of granules can be prepared in granular form by a conventionally known method of mixing the excipients, binders, disintegrants, etc. of the active ingredients of the present invention, and if necessary, flavoring agents, flavoring agents, etc. can

In addition, the pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. Any of the adjuvants known in the art may be used without limitation.

The pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. .

When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for suppositories, Witepsol, Tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol. In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners. The formulation may be prepared by conventional mixing, granulating or coating methods.

In addition, a typical formulation for parenteral administration is an injection formulation, and water, Ringer's solution, isotonic physiological saline or suspension may be used as a solvent for the injection formulation. Sterile fixed oils of the above injectable preparations may be used as a solvent or suspension medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides.

In addition, the formulation for injection may use a fatty acid such as oleic acid.

Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the following examples and experimental examples are presented as examples of the present invention, and if it is determined that detailed descriptions of well-known techniques or configurations may unnecessarily obscure the gist of the present invention, detailed descriptions thereof will be omitted. It can be done, and the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of the claims described below and equivalents interpreted therefrom.

<Example 1> Preparation of fermented arrowroot

Arrowroot purchased from Daegu Yangnyeong Market was pulverized, extracted with 30 (v/v)% alcohol at room temperature for 24 hours, concentrated and freeze-dried to prepare arrowroot extract. Lactobacillus paracasei JS1 (accession number: KCCM12288P) strain 1 (v/v)% and kudzu extract 2 (v/v)% were inoculated into the culture broth, fermented at 37℃ for 72 hours, concentrated and frozen It was dried to prepare fermented kudzu.

<Experimental Example 1> Confirmation of the improvement effect of premenstrual syndrome symptoms according to the treatment of kudzu fermented product

In this experiment, the effect of improving, preventing or treating premenstrual syndrome symptoms according to the treatment of arrowroot fermented product was confirmed.

Rats (wistar rats) were used after being acclimated to the breeding room environment for one week. The temperature of the breeding room was maintained at 25 ± 1 ℃, the humidity was maintained at 50-60%, the light-dark cycle was adjusted to a 12-hour cycle, and solid feed and water were supplied without restriction. Hereinafter, animal experiments were conducted according to the principles of guidelines provided by the Animal Experimentation Ethics Committee of Kyung Hee University. Each experimental group is shown in Table 1 below. Prefemin, a positive control group, is a drug that has an effect of improving, preventing or treating premenstrual syndrome, and has an effect of inhibiting prolactin secretion.

experimental group sample CON saline HPRL metoclopramide 150 mg/kg IDA metoclopramide 150 mg/kg
Iron deficient diet (AIN 93M) FS metoclopramide 150 mg/kg
Iron 4 mg/kg K metoclopramide 150 mg/kg
Arrowroot fermented product 200 mg/kg FS+K metoclopramide 150 mg/kg
Iron 4 mg/kg + arrowroot fermented product 200 mg/kg P metoclopramide 150 mg/kg
Prefemin 100 mg/kg

Eight rats were randomly assigned to each experimental group. All samples were used diluted in saline, and hyperprolactinemia (HPRL) was induced by intraperitoneal injection of 150 mg/kg of metoclopramide in all experimental groups except for the control group (CON). Metoclopramide is a substance used as an anti-emetic agent and is known to increase the secretion of prolactin through inhibition of dopamine secretion, thereby suppressing the secretion of progesterone, luteinizing hormone and follicle stimulating hormone (Wang et al., 2014). . In the IDA group, an iron deficiency model was induced simultaneously with hyperprolactinemia by using an iron-free diet. After inducing hyperprolactinemia for 10 days, each sample was orally administered daily according to the concentration, and the experiment was terminated by sacrificing the rats on the 22nd day from the start of administration. The blood of the sacrificed rats was collected, serum was separated, and prolactin, estradiol, luteinizing hormone (LH), follicle stimulating hormone (FSH), and prostaglandin E2 in the serum were collected. (prostaglandin E2, hereinafter referred to as PGE2), iron and hemoglobin secretion were analyzed to confirm the symptom improvement effect of premenstrual syndrome.

1-1. Weight-to-body weight measurement

The weights of the liver, kidney, spleen, thymus, and uterus of the sacrificed rats are shown in Table 2.

experimental group Liver Kidney Spleen Thymus Uterus CON 3.77±0.09 1.09±0.04 0.27±0.01 0.21±0.01 0.61±0.04 HPRL 3.83±0.07 1.10±0.02 0.24±0.01 0.22±0.01 0.64±0.05 IDA 3.58±0.12 1.06±0.03 0.26±0.02 0.22±0.01 0.66±0.05 FS 3.26±0.41 1.02±0.02 0.25±0.01 0.21±0.01 0.61±0.07 K 3.91±0.16 0.96±0.04 0.26±0.02 0.22±0.00 0.59±0.03 FS+K 3.76±0.07 1.06±0.02 0.25±0.01 0.21±0.01 0.51±0.02 P 3.67±0.05 1.04±0.03 0.22±0.01 0.19±0.01 0.50±0.04

As a result of measuring the weight of each organ, the weight of the uterus in the HPRL and IDA groups increased compared to the control group (CON), but there was no statistical difference. It was judged that there was no significant effect by substance administration.

1-2. Measurement of Prolactin in Rat Serum

In order to analyze the degree of alleviation of premenstrual syndrome symptoms of the subject, the amount of prolactin secretion in serum was measured using an ELISA kit (Molinnovation Co.). Figure 1 shows the amount of prolactin secretion.

As shown in FIG. 1, when the subject with hyperprolactinemia was treated with kudzu fermented product (K) alone or mixed with iron and kudzu fermented product (FS+K), the amount of prolactin secretion was effectively reduced. . In particular, compared to the case of treating iron (FS) and fermented kudzu (K) alone, the amount of prolactin secreted was lower when mixed with iron and fermented arrowroot (FS+K), and thus the premenstrual syndrome has been shown to be able to effectively improve

1-3. Measurement of Estradiol in Rat Serum

In order to analyze the degree of alleviation of premenstrual syndrome symptoms of the subject, the secretion of estradiol in serum was measured using an ELISA kit (Molinnovation Co.). Figure 2 shows the amount of estradiol secretion.

When hyperprolactinemia was induced, the amount of estradiol secretion was found to increase rapidly, and accordingly, when the amount of estradiol secretion decreased, it was judged that the premenstrual syndrome was improved. As shown in FIG. 2, it was found that, when hyperprolactinemia was induced in an individual treated with kudzu fermented product (K), the amount of estradiol secretion was significantly reduced, thereby effectively improving premenstrual syndrome.

1-4. Measurement of luteinizing hormone and follicle stimulating hormone in rat serum

In order to analyze the degree of relief of premenstrual syndrome symptoms of the subject, the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the serum was measured using an ELISA kit (Molinnovation Co.) . The amount of LH secretion in FIG. 3 and the amount of FSH secretion in FIG. 4 are shown.

Since the secretion of LH and FSH rapidly decreases during the luteal phase, it was judged that an increase in the secretion of LH and FSH showed an improvement in premenstrual syndrome. As shown in FIG. 3, it was confirmed that the amount of LH secretion increased when the hyperprolactinemia was induced in a mixture of iron and arrowroot fermented product (FS + K). In particular, iron and arrowroot fermented product (FS + K) treatment showed an effect of improving premenstrual syndrome by increasing LH secretion compared to iron (FS) alone or arrowroot fermented product (K) alone. On the other hand, as shown in FIG. 4, when the subject with hyperprolactinemia is treated with kudzu fermented product (K) alone or mixed with iron and kudzu fermented product (FS+K), the amount of FSH secretion increases. It has been shown to effectively improve premenstrual syndrome.

1-5. Measurement of prostaglandin E2 in rat serum

In order to analyze the degree of inflammation relief occurring in the uterus before and after menstruation, the secretion amount of prostaglandin E2 (hereinafter referred to as PGE2) in serum was measured using an ELISA kit (Molinnovation Co.). Figure 5 shows the secretion amount of PGE2.

As shown in FIG. 5, when the subject with hyperprolactinemia was treated with kudzu fermented product (K) alone or mixed with iron and kudzu fermented product (FS + K), the amount of PGE2 secretion was greatly reduced. . In particular, compared to the case where iron (FS) was treated alone and the fermented arrowroot (K) was treated alone, when iron and fermented arrowroot (FS+K) were mixed and treated, inflammation was alleviated or improved. was found to be remarkably high.

1-6. Measurement of iron and hemoglobin in rat serum

In order to analyze the degree of relief of anemia occurring before and after menstruation, the secretion of iron and hemoglobin in serum was measured using an ELISA kit (Molinnovation Co.). Figure 6 shows the amount of iron secretion, and Figure 7 shows the amount of hemoglobin secretion.

As shown in FIG. 6, it was found that the amount of iron secretion increased when the subject with hyperprolactinemia was treated with a mixture of fermented kudzu (K), iron and fermented kudzu (FS+K). On the other hand, as shown in FIG. 7, when the subject with hyperprolactinemia is treated with kudzu fermented product (K) alone or mixed with iron and kudzu fermented product (FS + K), hemoglobin secretion is found to increase. appear. Accordingly, it was determined that the present invention can alleviate or improve anemia occurring before and after menstruation by increasing the secretion of iron and hemoglobin as described above.

Korea Microbial Conservation Center (Overseas) KCCM12288P 20180713

Claims (7)

A food composition for improving premenstrual syndrome comprising kudzu fermented by inoculating kudzu extract with Lactobacillus paracasei JS1 (Accession No.: KCCM12288P) strain as an active ingredient. According to claim 1,
The arrowroot extract,
A food composition for improving premenstrual syndrome, characterized in that extracted with water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. According to claim 1,
The composition,
A food composition for improving premenstrual syndrome, further comprising iron. According to claim 1,
The fermentation product of kudzu,
A food composition for improving premenstrual syndrome, characterized in that it suppresses the secretion of prolactin, estradiol and PGE2. According to claim 1,
The fermentation product of kudzu,
A food composition for improving premenstrual syndrome, characterized in that it increases the secretion of LH and FSH. According to claim 1,
The fermentation product of kudzu,
A food composition for improving premenstrual syndrome, characterized in that it increases the secretion of iron and hemoglobin. A pharmaceutical composition for preventing or treating premenstrual syndrome comprising kudzu fermented by inoculating kudzu extract with Lactobacillus paracasei JS1 (accession number: KCCM12288P) strain and fermenting it as an active ingredient.

Images